article

Expert view: Delivering better therapeutics: fully characterising and recovering T cells

Posted: 1 June 2020 | | No comments yet

T cell-based therapies have shown promise as new treatment options for various cancers.

However, the functional heterogeneity of T cells can prove challenging during their development into therapeutics. These therapies have been associated with side effects relating to cytokine release syndrome (CRS) and neurotoxicity, placing extra importance on the understanding of functions such as cytokine release and killing kinetics at the single-cell level.











    To read this expert view in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


    *

    *

    *

    *

    *

    *

    *

    *

    This content is provided to you for free thanks to the kind support of our sponsor: Berkeley Lights

    Related organisations

    Send this to a friend